FDA commissioner says decision on psychedelic treatments will come quickly after Trump executive order sparks ibogaine interest

FDA commissioner Dr. Marty Makary says the government should deliver a speedy decision on psychedelic drugs that could help veterans with drug addiction and suicidal ideation. Makary frames the timeline as an obligation to veterans, linking the urgency to ongoing regulatory review. The report ties renewed public attention to President Donald Trump's executive order intended to spur research into psychedelic treatments, with ibogaine highlighted as a key example. The video describes how the order has increased interest in psychedelics for conditions such as PTSD and other mental health related problems.